论文部分内容阅读
目的探讨艾迪注射液辅助化疗治疗胃癌患者的临床疗效。方法回顾性分析沈阳医学院附属中心医院确诊为胃癌并接受化疗的160例患者资料,依照艾迪注射液使用情况分为两组,即艾迪注射液联合化疗组(即联合组)87例和单用化疗组(即对照组)73例。化疗4个疗程后,比较分析化疗前后两组患者免疫状态、生命质量评分变化,并对肿瘤控制效果进行比较,同时统计化疗期间患者化疗不良反应发生情况。结果化疗后,联合组患者血清CD3+、CD4+、CD8+、CD4+/CD8+显著优于对照组,差异均有统计学意义(均P<0.05);联合组患者生命质量改善率、肿瘤总缓解率均显著高于对照组,差异均有统计学意义(均P<0.05);联合组患者化疗不良反应发生率显著低于对照组,差异有统计学意义(P<0.05)。结论艾迪注射液辅助化疗能够提高胃癌患者免疫功能,改善其生命质量,对于改善肿瘤疗效有促进作用,且安全性较高。
Objective To investigate the clinical effect of Aidi injection adjuvant chemotherapy in patients with gastric cancer. Methods A retrospective analysis of Shenyang Medical College Affiliated Central Hospital diagnosed with gastric cancer and chemotherapy in 160 patients, according to the use of Aidi injection is divided into two groups, namely, Aidi injection combined chemotherapy group (ie, combination group) 87 cases and The chemotherapy alone group (control group) 73 cases. After 4 cycles of chemotherapy, the immune status and quality of life scores of two groups before and after chemotherapy were compared, and the effect of tumor control was compared. At the same time, the incidence of adverse reactions of chemotherapy during chemotherapy was counted. Results After chemotherapy, the serum levels of CD3 +, CD4 +, CD8 + and CD4 + / CD8 + in the combined group were significantly better than those in the control group (all P <0.05); the quality of life improvement and overall tumor remission rate were significantly higher in the combined group (P <0.05). The incidence of adverse reactions of chemotherapy in the combination group was significantly lower than that in the control group, the difference was statistically significant (P <0.05). Conclusion Aidi injection adjuvant chemotherapy can improve the immune function of patients with gastric cancer, improve their quality of life, to improve the efficacy of the tumor has a promoting effect, and high safety.